Stockscreener 앱 받기
4.16
2.35%
-0.10
시간 외 거래:
4.20
0.04
+0.96%
전일 마감가:
$4.26
열려 있는:
$4.2
하루 거래량:
5.81M
Relative Volume:
3.02
시가총액:
$696.31M
수익:
$25.55M
순이익/손실:
$-341.97M
주가수익비율:
-1.5465
EPS:
-2.69
순현금흐름:
$-304.44M
1주 성능:
-11.68%
1개월 성능:
-10.73%
6개월 성능:
-39.27%
1년 성능:
-60.42%
1일 변동 폭
$4.15
$4.315
1주일 범위
$4.11
$5.025
52주 변동 폭
$4.11
$12.14
릴레이 테라퓨틱스 Stock (RLAY) Company Profile
명칭
Relay Therapeutics Inc
전화
617-370-8837
주소
399 BINNEY STREET, CAMBRIDGE
RLAY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RLAY
Relay Therapeutics Inc
|
4.16 | 696.31M | 25.55M | -341.97M | -304.44M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
릴레이 테라퓨틱스 Stock (RLAY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-10 | 재개 | Goldman | Buy |
| 2024-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-09-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-05-10 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-04-20 | 업그레이드 | Jefferies | Underperform → Hold |
| 2023-04-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-04-13 | 개시 | Raymond James | Outperform |
| 2023-02-03 | 개시 | Oppenheimer | Outperform |
| 2022-09-30 | 개시 | Barclays | Equal Weight |
| 2022-09-02 | 개시 | Stifel | Buy |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-02-01 | 개시 | Berenberg | Buy |
| 2021-07-21 | 개시 | BofA Securities | Buy |
| 2020-12-15 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-08 | 개시 | JMP Securities | Mkt Outperform |
| 2020-11-05 | 개시 | H.C. Wainwright | Buy |
| 2020-08-10 | 개시 | Cowen | Outperform |
| 2020-08-10 | 개시 | Goldman | Buy |
| 2020-08-10 | 개시 | Guggenheim | Buy |
| 2020-08-10 | 개시 | JP Morgan | Neutral |
모두보기
릴레이 테라퓨틱스 주식(RLAY)의 최신 뉴스
Intrahepatic Cholangiocarcinoma Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapeutics - The Globe and Mail
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Relay Therapeutics Inc (RLAY) Volatility Hits 7.89% – Here Is What You Should Do - Stocks Register
Relay Therapeutics stock hits 52-week low at $4.25 By Investing.com - Investing.com Canada
Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 100,000 Shares - MarketBeat
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year LowHere's What Happened - MarketBeat
Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock - Investing.com
Relay Therapeutics CEO Sanjiv Patel sells $500,000 in stock By Investing.com - Investing.com UK
Relay Therapeutics stock hits 52-week low at $4.25 - Investing.com
HighTower Advisors LLC Cuts Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Sold by HighTower Advisors LLC - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.4%Time to Sell? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.58 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Relay Therapeutics: A Hidden Gem in Cancer Treatment with RLY-2608's Potential to Revolutionize Breast Cancer Care - mediahousepress
Relay Therapeutics' SWOT analysis: stock's potential in PI3K inhibitor race By Investing.com - Investing.com Australia
Relay Therapeutics' SWOT analysis: stock's potential in PI3K inhibitor race - Investing.com India
Relay Therapeutics’ (RLAY) Market Outperform Rating Reiterated at JMP Securities - Defense World
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory - MSN
Relay Therapeutics stock holds Buy rating, BofA highlights $1bn+ peak sales potential for RLY-2608 - Investing.com Nigeria
Relay Therapeutics' (RLAY) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - Marketscreener.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Charles Schwab Investment Management Inc. - MarketBeat
Layoff Tracker: Bavarian, BenevolentAI, Chroma Medicine and Nvelop Therapeutics Cut Staff - BioSpace
Relay Therapeutics Announces Updated Interim Data for - GlobeNewswire
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival - GlobeNewswire Inc.
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar - BioCentury
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium - The Manila Times
Relay Therapeutics to Present Updated Clinical Data on - GlobeNewswire
Elevar Therapeutics’ Global Licensing Agreement with Relay Therapeutics - Global Legal Chronicle
1,349,400 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Bought by Point72 Asset Management L.P. - MarketBeat
FY2024 Earnings Forecast for RLAY Issued By Leerink Partnrs - MarketBeat
HC Wainwright Predicts Lower Earnings for Relay Therapeutics - MarketBeat
Leerink Partners Cuts Relay Therapeutics (NASDAQ:RLAY) Price Target to $18.00 - Defense World
Leerink Partnrs Has Positive Outlook of RLAY FY2024 Earnings - Defense World
Relay Therapeutics price target lowered to $18 from $19 at Leerink - MSN
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) - Yahoo Finance
Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? - Insider Monkey
Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal - BioWorld Online
Relay Therapeutics stock sees target decrease, strong potential for lirafugratinib - Investing.com
Relay Therapeutics stock target cut by Leerink amid licensing agreement - Investing.com UK
Maven Securities LTD Takes $2.39 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
Relay Therapeutics stock hits 52-week low at $4.48 By Investing.com - Investing.com South Africa
Relay Therapeutics stock hits 52-week low at $4.48 - Investing.com
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - The Manila Times
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors - GlobeNewswire
Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials (NASDAQ:RLAY) - Seeking Alpha
Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Bought by Bellevue Group AG - MarketBeat
Braidwell LP Grows Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY) - MarketBeat
릴레이 테라퓨틱스 (RLAY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.88%
2.65%
자본화:
|
볼륨(24시간):